Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron has more growth opportunities ahead ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Three stocks which have generated 100-bagger returns for investors over the past 20 years are Booking Holdings (NASDAQ: BKNG), Apple (NASDAQ: AAPL), and Regeneron Pharmaceuticals (NASDAQ: REGN).